Vietnam Drug Administration Cites Nine Pharmas For Violating Ad Rules
This article was originally published in PharmAsia News
Executive Summary
The Drug Administration of Vietnam has cited nine pharmaceutical companies for violating its regulation regarding advertisements of their products. According to the agency, the nine firms ran ads with unapproved information or in advance of registering with the agency. Among those cited were Ebewe Pharma of Austria, Getz Pharma of Pakistan, Kim Do and Sanofi Aventis. The nine firms were placed on three months suspension, meaning the agency would not accept any proposed advertisements for airing. It also could impose more penalties if violations continue, the agency said. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.